ANGPTL8 antisense oligonucleotide

2 papers3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

2 independent labs in 1 country

Funders: Huazhong University of Science and Technology and 3 more

Animals1
Cells1

Outcomes

Vascular function

upin mice1

1 study

ANGPTL8 antisense oligonucleotide improves vascular function in mice.
“In vivo, Angptl8 deletion or ASO reduced aortic senescence/inflammation markers and improved vascular function versus WT T2DM mice.”
Animalsin T2DM miceaorta
ANGPTL8 Promotes Endothelial Senescence in Type 2 Diabetes via RTN4R-PI3K/AKT/FOXO3A
ADA Scientific Sessions 2026 abstract5 Jun 2026

Cellular senescence

downin mice1

1 study

ANGPTL8 antisense oligonucleotide decreases cellular senescence in mice.
“In vivo, Angptl8 deletion or ASO reduced aortic senescence/inflammation markers and improved vascular function versus WT T2DM mice.”
Animalsin T2DM miceaorta
ANGPTL8 Promotes Endothelial Senescence in Type 2 Diabetes via RTN4R-PI3K/AKT/FOXO3A
ADA Scientific Sessions 2026 abstract5 Jun 2026